Glenmark Pharmaceuticals Inc. has launched Methylene Blue Injection USP in the United States. This bioequivalent generic aims to expand the company's institutional portfolio and provide affordable medicine.

Glenmark Pharmaceuticals Launches Methylene Blue Injection in US

Glenmark Pharmaceuticals Inc., USA has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the United States market. This new product is bioequivalent and therapeutically equivalent to ProvayBlue Injection by Provepharm SAS.

Reader Takeaway: New generic launch expands US institutional offerings; faces potential indication limitations.

What just happened

Glenmark Pharmaceuticals Inc. announced the launch of Methylene Blue Injection USP in the US. This injection is a generic version of ProvayBlue Injection, referencing an approved New Drug Application (NDA 204630).

Why this matters

This launch is part of Glenmark's strategy to grow its institutional portfolio and provide access to affordable medicines for healthcare institutions in the U.S. The reference drug had annual sales of $19.0 million for the 12 months ending April 2026.

The backstory

Glenmark Pharmaceuticals is a global research-driven pharmaceutical company focused on developing and marketing affordable, high-quality medicines.

What changes now

The company strengthens its U.S. commercial presence with this addition to its institutional product offerings.

Risks to watch

A key watch point is that the product's approved indications may differ from the reference drug, potentially limiting its market scope as stated in company approval documentation.

Peer comparison

Glenmark operates in the generic pharmaceutical space, competing with other companies that launch bioequivalent and therapeutically equivalent products.

Context metrics (time-bound)

The reference drug, ProvayBlue Injection, had annual sales of $19.0 million for the 12 months ending April 2026.

What to track next

Investors should monitor the market adoption and sales performance of Methylene Blue Injection within the U.S. institutional segment.